Schmidt, Marcus
Lenhard, Hans
Hoenig, Arnd
Zimmerman, Yvette
Krijgh, Jan
Jansen, Monique
Coelingh Bennink, Herjan J. T. http://orcid.org/0000-0003-1550-9400
Funding for this research was provided by:
Pantarhei Oncology
Article History
Received: 29 September 2020
Accepted: 13 November 2020
First Online: 26 November 2020
Compliance with ethical standards
:
: MS received Grants and personal fees from Pierre-Fabre and BioNTech; personal fees and non-financial support from Roche, Amgen and Pfizer; personal fees from Novartis, Astra-Zeneca, Celgene and Eisai, outside the submitted work. HL has nothing to disclose. AH obtained grants and personal fees from Roche and Genentech, personal fees and non-financial support from Roche, Amgen and Pfizer; personal fees from Novartis, Astra-Zeneca, PharMar and Celgene. JK is CMO of Pantarhei Oncology. MJ is an independent consultant and the project manager of the ABCE4 study. YZ is CEO of Pantarhei Bioscience and Pantarhei Oncology, and shareholder of Pantarhei Oncology. HCB is President and shareholder of Pantarhei Bioscience and Pantarhei Oncology.
: All procedures performed in this study were in accordance with GCP, with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the independent ethics committee Landesärztekammer Rheinland-Pfalz. Informed consent was obtained from all individual participants participating in the study.
: MS/HL/AH and HCB contributed to the concept and design of the study. MS/HL/AH recruited and treated the patients. All authors analyzed and interpreted the results and patient data and read and approved the final manuscript.